Atypical presentation of Hodgkin's disease in a patient at risk for the acquired immunodeficiency syndrome.

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Atypical presentation of Hodgkin's disease in a patient at risk for the acquired immunodeficiency syndrome.

Cancer Detect Prev. 1988;12(1-6):243-8. Unique Identifier : AIDSLINE MED/89028468
Keyserlingk H; Ludwig WD; Seibt H; Ruhl H; Hoffken G; Department of Hematology and Oncology, University Medical Center; Steglitz, Free University of Berlin, West Berlin, Federal; Republic of Germany.

Abstract: Hodgkin's disease (HD) has been reported in association with the acquired immunodeficiency syndrome (AIDS) only occasionally, and these patients seemed to have aggressive unusual HD. We report an additional case of HD in a 50-year-old homosexual man with a marked change of his clinical course after the development of seropositivity to human immunodeficiency virus (HIV). In 1978, HD stage IIIA, nodular sclerosing type, was diagnosed and treated with splenectomy and total nodal radiotherapy, which led to a complete response lasting till 1985. The patient then reported to our clinic with generalized lymphadenopathy and paresis of the m. biceps and m. triceps due to an infiltration of C6/C7 by HD. Laboratory findings revealed a T4/T8 ratio of 0.5 and HIV antibodies. He was given chemotherapy (COPP), but after a good initial response he developed pulmonary infiltration of HD. Therapy was changed to ABVD, but the patient did not respond to treatment and died of progressive HD in 1986. We therefore conclude that the natural history of HD in patients at risk for AIDS may be altered to a higher malignant form, and treatment modalities used in these patients must be further evaluated.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Antineoplastic Agents, Combined/THERAPEUTIC USE Case Report Cyclophosphamide/ADMINISTRATION & DOSAGE Hodgkin's Disease/ETIOLOGY/*PATHOLOGY Human HIV Seropositivity Male Middle Age Prednisone/ADMINISTRATION & DOSAGE Procarbazine/ADMINISTRATION & DOSAGE Risk Factors Vincristine/ADMINISTRATION & DOSAGE JOURNAL ARTICLE

890228
M8920474

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .